首页> 美国卫生研究院文献>Clinical and Diagnostic Laboratory Immunology >Enzyme-Linked Immunosorbent Assay for Recombinant K39 Antigen in Diagnosis and Prognosis of Indian Visceral Leishmaniasis
【2h】

Enzyme-Linked Immunosorbent Assay for Recombinant K39 Antigen in Diagnosis and Prognosis of Indian Visceral Leishmaniasis

机译:酶联免疫吸附法检测重组K39抗原在印度内脏利什曼病的诊断和预后中

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The recombinant product (rK39) of the 39-amino-acid repeats encoded by a kinesin-like protein-encoding gene of Leishmania chagasi was evaluated by enzyme-linked immunosorbent assay (ELISA) for diagnostic potential and the ability to predict the response to therapy in Indian kala-azar or visceral leishmaniasis (VL); we also compared its performance with that of crude soluble antigen (CSA). At the diagnosis of VL, the anti-rK39 antibody titer was 59-fold higher than the anti-CSA antibody titer. With successful therapy, antibody titers declined steeply at the end of treatment and during follow-up. In contrast, patients who relapsed showed increased titers of antibodies to rK39. The extremely high levels of anti-rK39 antibodies in VL cases suggest the application of rK39 for sensitive and specific serodiagnosis, and rK39 ELISA is also valuable in monitoring drug therapy and detecting relapse of the disease.
机译:通过酶联免疫吸附测定(ELISA)评估了利什曼原虫(Leishmania chagasi)的类似驱动蛋白的蛋白编码基因编码的39个氨基酸重复序列的重组产物(rK39)的诊断潜力和预测对治疗反应的能力印度黑热病或内脏利什曼病(VL);我们还比较了其与粗制可溶性抗原(CSA)的性能。诊断为VL时,抗rK39抗体滴度比抗CSA抗体滴度高59倍。通过成功的治疗,抗体滴度在治疗结束时和随访期间急剧下降。相反,复发的患者显示抗rK39抗体滴度增加。 VL病例中高水平的抗rK39抗体表明rK39在敏感和特异性血清诊断中的应用,rK39 ELISA在监测药物治疗和检测疾病复发方面也很有价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号